Get Your Product Development Plan for Early-Stage Companies

*Investor-ready* product development plan including detailed GANTT chart with milestones, critical path and itemized budget.

In cooperation with California Life Sciences Association, PharmaDirections is sponsoring the JumpStart Grant. Having a detailed, comprehensive and well-conceived development plan is *critical* to raising venture rounds and executing efficiently. The development plan and GANTT chart you will receive from this grant will be investor-ready.

PharmaDirections will be awarding a single grant to the winner.

Approximate value of the JumpStart Service Grant (non-cash grant) is $25,000.

**TO APPLY**

Please go to the below website where you will find a link to apply, as well as detailed information about the grant and the application process.

[www.pharmadirections.com](http://www.pharmadirections.com)

All applications MUST be submitted by midnight on **September 17, 2015**. No exceptions.

Please contact GrantCA@PharmaDirections.com with questions.

**Grant website available:** June 29

**Applications Due:** September 17

**Award recipients will be announced** November 19, 2015
Eligibility

Companies applying for the JumpStart Grant must meet the following criteria:

- Must be headquartered in California or be a California Life Science Association member company
- Academic-base companies or programs must be located at universities in California
- Product must be a therapeutic (small molecule, large molecule, vaccine or biologic) or a drug-device combination
- Diagnostics and medical devices are NOT eligible for the JumpStart Grant
- Must be a privately-held company

Key Dates

- Official Announcement at BayBio’s FAST Spring Showcase June 9
- Grant Application Deadline September 17
- Announce Winner November 19 at Bay Bio’s FAST Fall Showcase

Product Development Plan:

Description of CMC activities required to support the IND submission

- How to provide material for the toxicology program and first-in-human clinical study
- API process development and GMP production, formulation development, drug product process development and GMP production

Discussion of the proposed nonclinical program to support the IND submission for the intended indication, including justification

- Safety pharmacology, genotox, general toxicology, special toxicology
- Bioanalytical assay development and validation
- ADME

Overall regulatory strategy

High-level synopsis for the first-in-human clinical study

A detailed budget including selection of clinical CRO (approximate timeline and budget for clinical plan)

A Gantt chart with all critical development activities & studies